Research On The Influcing Factors Of Pharmaceutical Companies' Technology Innovation

China's pharmaceutical market shows a typical "dual structure". Multinational companies depend on the brand drugs to occupy the high-end market. Domestic pharmaceutical companies compete with the price in the low-end market on the generic drugs. China has tremendous medicine market. It is inevitable that multinational companies will expand further in the domestic market. Faced with the growing international market of China, China's pharmaceutical enterprises have entered a crucial stage for the autarkic innovation.To enhance the ability of pharmaceutical companies' technological innovation, we should know the variables influencing the pharmaceutical technological innovation. Which are the key factors? What are the differences or gaps from the developed countries on these factors? Then, we can learn the experience from the foreign countries to make more reasonable policies according to the local conditions. Therefore, this paper's aim is to provide reference for policy makers by establishing a macroscopic framework that influence the pharmaceutical companies' technological innovation and giving a microscopic comparison with the foreign countries to find the difference on these variables.Because the process and characteristics of pharmaceutical technology innovation in our country are the same as foreign countries, we established a framework for influencing factors according to the related studies in Italy, Australia and Britain. We concluded 27 variables and 16 key factors that influence the pharmaceutical companies' technology innovation. A dominant advantage for the theories of value chain is the systemic. The dissertation applied the structure of pharmaceutical industry network to research the variables of pharmaceutical technology innovation. The variables are classified into three categories: the variables that is about the actions to principle value chain by assistant value chain; variables on principle value chain; variables in the environment of value network. By comparing with the foreign countries, we fund the difference in these variables and concluded four actions to principle value chain by assistant value chain: First, regulate the actions of the bodies on principle value chain. Second, promote the principle value chain to get resources. Third, improve the innovation efficiency of the principle value chain by ensuring the enterprises get the longest patent period .Fourth, push the innovation companies to get the revenue. There are five differences in pharmaceutical innovation value network between China and England or America. First, the encouraging function by assistant value chain to the principle value chain is not sufficient. Second, the regulation is not suitable. Third, the fluent of the value can't maximize the value of the chain. Fourth, as the bodies in value unit are excessive, the structure of value network is loose. Fifth, the environment of the network should to be improved.Finally, in view of the existing problems in the pharmaceutical innovation value network , the dissertation bring forward five proposals: First, integrate the value of pharmaceutical innovation value network to a more close structure. Second, strengthen the government investment especially to the clinical value unit. Third, improve the motivation of technology innovation by resolving the problems with the variable of pricing, reimbursement and uptake of the medicine. Fourth, the government should make a more strict supervision or management to ensure drug quality which is the premise of fair competition and to accelerate the pharmaceutical companies with low drug quality level to withdraw the market. Fifth, encourage the companies to invest long-time and get the resources by improving the environment of the value network.